Digital Landscape: Multiple Sclerosis

About the Report

About the Report

Digital Landscape: Multiple Sclerosis




The Digital Landscape Multiple Sclerosis report analyzes digital activities undertaken by Pharma in support of disease-modifying therapies for Multiple Sclerosis (MS).


Key Highlights


- US Patients: Overall, digital pharma support is strong for MS patients in the US; good quality branded and unbranded resources detected, particularly from Biogen, Teva and Sanofi Genzyme. Patients are well supported by social media, with branded Facebook pages from Teva, Novartis and EMD Serono the most successful. Less mobile app activity seen, with top offerings from branded treatment trackers, with Bayer's new app achieving early success.

- US HCPs: There is little support for HCPs in the MS space beyond branded, with Genzyme, Biogen, and Teva offering the best branded resources. The pharma-sponsored unbranded and mobile app landscapes are sparse, and opportunities may exist to develop or sponsor content with trusted non-pharma organizations. HCP-directed social media activity restricted to posts from corporate accounts, with examples of HCP-specific accounts seen in other diseases.

- EUCAN Patients: MS patients in EUCAN are well supported by pharma overall, particularly those in Germany. Support is weakest in the UK and Canada. Best branded support seen from Sanofi Genzyme, Teva and Merck KGaA, with most brand activity related to patient support programs. Pharma provides strong unbranded support but no multi-country, local-language campaigns, with the majority of sites are supported by social media. Pharma-sponsored mobile app landscape is strong, particularly from Novartis, with common features including disease tracking and reminders.

- EUCAN HCPs: Limited HCP support provided by pharma in MS beyond brand sites. Merck KGaA and Sanofi Genzyme offer the best branded support, with a number of sites detected across EUCAN. The unbranded and mobile app landscapes are undeveloped, and like the US, partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.




- This report analyzes digital activities undertaken by Pharma in support of disease-modifying therapies for MS.

- The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.

- The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.

- The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.

- This report covers the research period from January-December 2017.


Reasons to buy


- Our Digital Landscape report provides an analysis of Pharma multichannel activity in the digital MS space, and can assist our Pharma clients derive value in a number of ways:

- Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in MS

- Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns

- Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands

- Business Development & Licensing: Assess topics and trends shaping digital health in MS and beyond, and learn about key patient and physician online activities in MS.




Sanofi Genzyme


Merck KGaA / EMD Serono

Roche / Genentech







Table of Contents

Table of Contents

Table of Contents

Executive Summary

Recent Developments

Landscape & Analysis

US: Patient-directed Activities

US HCP-directed Activities

EUCAN Patient-directed Activities

EUCAN HCP-directed Activities


You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us

Want the same for your business? Talk To Our Expert